ABBV vs BMY
ABBV and BMY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABBVAbbVie Inc. | BMYBRISTOL-MYERS SQUIBB COMPANY |
|---|---|---|
| Market cap | $451.60B | $136.00B |
| P/E (TTM) | 72.2 | 14.7 |
| P/B | — | 6.09 |
| P/S | 7.4x | 2.8x |
| Dividend yield | 2.58% | 3.71% |
| Revenue | $61.16B(TTM) | $49.19B(TTM) |
| Revenue growth (YoY) | 8.6% | -0.2% |
| Net income | $6.31B(TTM) | $9.28B(TTM) |
| Earnings growth (YoY) | -1.2% | 178.8% |
| EPS, diluted | $3.54(TTM) | $4.54(TTM) |
| EBIT margin | 24.6% | 21.8% |
| ROE | — | 31.6% |
| ROIC | 18.6% | 14.0% |
| Piotroski F | — | 7/9 |
| 1y total return | +26.1% | +47.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABBV vs BMY
| Metric | ABBV | BMY |
|---|---|---|
| End value | $64.0K | $13.6K |
| Total return | +540.0% | +35.6% |
| CAGR | +19.7% | +3.0% |
| Volatility | 25.9% | 25.3% |
| Sharpe | 0.68 | 0.09 |
| Sortino | 0.94 | 0.12 |
| Max drawdown | -45.1% | -47.7% |
Based on 2600 common trading days, 2016-04-27 → 2026-08-28 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)